Activation of CD40 by soluble recombinant human CD40 ligand inhibits human glioma cells proliferation via nuclear factor-κB signaling pathway.
10.1007/s11596-012-1019-1
- Author:
Yong ZHANG
1
;
Tao HUANG
;
Yi HU
;
Yu WANG
Author Information
1. Department of Dermatology, Huazhong University of Science and Technolgoy, Wuhan, China. zhangyongtj@gmail.com
- Publication Type:Journal Article
- MeSH:
CD40 Antigens;
metabolism;
CD40 Ligand;
metabolism;
Cell Proliferation;
Cells, Cultured;
Glioma;
genetics;
metabolism;
pathology;
Humans;
NF-kappa B;
metabolism;
Signal Transduction;
physiology;
Tumor Cells, Cultured
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2012;32(5):691-696
- CountryChina
- Language:English
-
Abstract:
As CD40 transduces activation signals involved in inflammatory and immune disorders, we explored the expression and response to CD40 engagement in human glioma cell lines in this study. The CD40 expression in BT-325 and U251 cells was flow cytometrically detected. The cells were incubated with srhCD40L for 72 h to assess its effects on cell growth in vitro. TNF-α expression was quantified by real-time PCR, and protein expression was analyzed by ELISA. The I-κb mRNA was detected by RT-PCR. I-κB expression decreased after stimulation with 1 μg/mL srhCD40L, but it was upregulated after the cells were pretreated with CD40 antibody. srhCD40L significantly inhibited the proliferation of the CD40+ human glioma cells. The stimulation of CD40+ glioma cells with soluble CD40L (CD154) up-regulated the expression of TNF-α at both mRNA and protein levels. We are led to conclude that CD40L/CD40 could inhibit human glioma cells through I-κb signaling pathway. Interferon-γ can augment CD40 expression and the inhibitory effect of CD40 ligand on cell growth in vitro. These results suggest that srhCD40L may benefit the therapy strategy of glioma.
